Diagnostic Evaluation of Viral Persistence in Cervical Cancer

NCT07325682 | Enrolling By Invitation

• 1 other identifier: CC-DIAG-001
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the diagnostic value of an electroacupuncture-based method for detecting viral persistence (human papillomavirus and SARS-CoV-2) in patients with cervical cancer. The study investigates whether persistent viral signatures can be identified through measurable electrodiagnostic responses at acupuncture points associated with organ systems affected by chronic viral infection. The goal is to assess the feasibility, reproducibility, and potential clinical relevance of this diagnostic approach in oncology patients.

Conditions

Cervical Cancer

Keywords

medicament testing; viral antigen persistance; Human Papillomavirus

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Bioelectrical Patterns Consistent With Viral Antigen Persistence

  Diagnostic assessment to identify bioelectrical response patterns associated with viral antigen persistence in cervical cancer patients using a non-invasive bioelectrical testing approach.

  At enrollment (single diagnostic session)

Study Arms (1)

Diagnostic Group

EXPERIMENTAL

Non-invasive diagnostic method assessing bioelectrical response patterns associated with viral markers in patients with cervical cancer.

Diagnostic Test: Electroacupuncture

Interventions

Electroacupuncture DIAGNOSTIC_TEST

Non-invasive electrodiagnostic assessment using electroacupuncture measurements to evaluate bioelectrical response patterns associated with viral markers in patients with cervical cancer.

Diagnostic Group

Eligibility Criteria

• Age: 21 Years - 70 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically confirmed cervical cancer (FIGO stage IIIA-IVA)
• Age ≥21 years
• ECOG performance status adequate for diagnostic procedures
• Adequate organ function
• Ability to provide informed consent

You may not qualify if:

• Poor renal function (elevated creatinine)
• Significant liver dysfunction (elevated bilirubin or liver enzymes)
• Severe cardiovascular or pulmonary disease
• Pregnancy or breastfeeding
• Severe mental illness or inability to provide informed consent
• Known non-compliance or substance abuse

Sponsors & Collaborators

• Oncology Center,Ministry Of Heath,Uzbekistan: lead

Study Sites (1)

City Branch of the National Oncology and Radiology Center

Tashkent, 100154, Uzbekistan

Location

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Masking Details: Diagnostic evaluation of viral persistence using EAV-based measurement of viral activity in cervical cancer patients.
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: December 9, 2025
• First Posted: January 8, 2026
• Study Start: April 30, 2025
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): December 30, 2030
• Last Updated: January 8, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

UZ (1)